Detalhe da pesquisa
1.
Genome-wide association study identifies high-impact susceptibility loci for HCC in North America.
Hepatology
; 2024 Feb 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-38381705
2.
Convergent MAPK pathway alterations mediate acquired resistance to FGFR inhibitors in FGFR2 fusion-positive cholangiocarcinoma.
J Hepatol
; 80(2): 322-334, 2024 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-37972659
3.
Revisiting the Malignant Masquerade at the Liver Hilum: Have We Made Progress?
Ann Surg Oncol
; 31(5): 3062-3068, 2024 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-38282027
4.
Safety and Efficacy of Immune Checkpoint Inhibitors in Patients with Cancer and Viral Hepatitis: The MD Anderson Cancer Center Experience.
Oncologist
; 28(8): 714-721, 2023 08 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36952233
5.
Development of a Novel Comprehensive Hepatocellular Carcinoma Outcome Prognostic Scoring System With Integration of Imaging Features.
Oncologist
; 2023 Dec 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-38159256
6.
Brain Metastases from Biliary Tract Cancer: Case Series and Clinicogenomic Analysis.
Oncologist
; 28(4): 327-332, 2023 04 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-36715178
7.
Clinical and Prognostic Biomarker Value of Blood-Circulating Inflammatory Cytokines in Hepatocellular Carcinoma.
Oncology
; 101(11): 730-737, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37467732
8.
Ablative liver radiotherapy for unresected intrahepatic cholangiocarcinoma: Patterns of care and survival in the United States.
Cancer
; 128(13): 2529-2539, 2022 07 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35417569
9.
Plasma Growth Hormone as a Prognostic Biomarker to Durvalumab and Tremelimumab in Patients with Advanced Hepatocellular Carcinoma.
J Hepatocell Carcinoma
; 11: 455-461, 2024.
Artigo
em Inglês
| MEDLINE | ID: mdl-38463542
10.
Phase I Trial of SPECT-Guided Liver-Directed Radiotherapy for Patients with Low Functional Liver Volume.
JNCI Cancer Spectr
; 2024 May 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-38730548
11.
Evidence to Date: Clinical Utility of Tremelimumab in the Treatment of Unresectable Hepatocellular Carcinoma.
J Hepatocell Carcinoma
; 10: 1911-1922, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37915617
12.
Salvage Locoregional Therapy Following Progression After Radiotherapy for Hepatocellular Carcinoma Is Associated with Improved Outcomes.
J Gastrointest Surg
; 27(9): 1867-1875, 2023 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-37268830
13.
The Gut Microbiome as a Biomarker and Therapeutic Target in Hepatocellular Carcinoma.
Cancers (Basel)
; 15(19)2023 Oct 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-37835569
14.
Definitive Liver Radiotherapy for Intrahepatic Cholangiocarcinoma with Extrahepatic Metastases.
Liver Cancer
; 12(3): 198-208, 2023 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-37593365
15.
Genetic features and therapeutic relevance of emergent circulating tumor DNA alterations in refractory non-colorectal gastrointestinal cancers.
Nat Commun
; 13(1): 7477, 2022 12 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36463294
16.
Outcomes and Toxicities of Modern Combined Modality Therapy with Atezolizumab Plus Bevacizumab and Radiation Therapy for Hepatocellular Carcinoma.
Cancers (Basel)
; 14(8)2022 Apr 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-35454808
17.
Plasma growth hormone is a potential biomarker of response to atezolizumab and bevacizumab in advanced hepatocellular carcinoma patients.
Oncotarget
; 13: 1314-1321, 2022 12 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-36473155
18.
Perioperative nivolumab monotherapy versus nivolumab plus ipilimumab in resectable hepatocellular carcinoma: a randomised, open-label, phase 2 trial.
Lancet Gastroenterol Hepatol
; 7(3): 208-218, 2022 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-35065057
19.
Systemic therapy of liver cancer.
Adv Cancer Res
; 149: 257-294, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-33579425
20.
Current Landscape and Future Directions of Biomarkers for Immunotherapy in Hepatocellular Carcinoma.
J Hepatocell Carcinoma
; 8: 1195-1207, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-34595140